Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8277153 | 0.78 | DPP4 (0.64) | DPP4DPP8CYP3A4 | |
| SCHEMBL21986813 | 0.69 | DPP4 (0.58) | DPP4DPP8 | |
| SCHEMBL1996169 | 0.67 | PARP1 (0.54) | DPP4DPP8 | |
| SCHEMBL17308779 | 0.66 | DPP4 (0.49) | DPP4DPP8 | |
| SCHEMBL3145087 | 0.66 | DPP4 (1.00) | DPP4DPP8 | |
| SCHEMBL3149198 | 0.65 | DPP4 (1.00) | DPP4DPP8 | |
| SCHEMBL29624840 | 0.65 | AHR (0.64) | CYP3A4 | |
| SCHEMBL464507 | 0.65 | AHR (0.64) | CYP3A4 | |
| SCHEMBL1995841 | 0.63 | DPP4 (0.46) | DPP4DPP8CYP3A4 | |
| SCHEMBL4080406 | 0.63 | DPP4 (0.46) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | claimed |
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | claimed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | claimed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885CYP3A4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.